Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Kerri McCullough Wood Named Chief Commercial Officer at Avid Bioservices

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kerri McCullough Wood as Chief Commercial Officer. McCullough Wood is a seasoned biopharma executive with...

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI® (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or...

Avenacy Announces U.S. Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Tranexamic Acid in 0.7% Sodium Chloride Injection in the United States. The product contains the same active ingredient as...

Viralgen Teams with Elaaj Bio to Advance CDKL5 Deficiency Gene Therapy

Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development...

Study Finds Testosterone Therapy Boosts Women’s Energy, Mood, and Quality of Life

Joi + Blokes, a telehealth platform specializing in diagnostic testing, personalized medicine, and hormone and menopause care, announced the publication of a new peer-reviewed study demonstrating that testosterone replacement therapy (TRT) in...

BioOra Limited and Wellington Zhaotai Therapies Limited (WZTL) Execute Heads of Terms to Accelerate Global Expansion of CAR T-Cell Therapy

BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, announced the signing of a binding Heads of Terms agreement with Wellingto. Zhaotai Therapies Limited (Wellington Zhaotai) under which...

Elizabeth Nanouris Named VP of Business Operations at InFocus Clinical Research

InFocus Clinical Research, the only global, full-service retina specialty contract research organization, announced that Elizabeth Nanouris has joined InFocus as vice president of business operations. Nanouris joins a robust operations team and...

Novo Nordisk’s Ozempic pill—the only FDA-approved oral peptide GLP-1 for adults with Type 2 Diabetes—will soon be available in the U.S

Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with...

Incyte announces FDA approval of Jakafi XR for treating myelofibrosis, polycythemia vera, and graft-versus-host disease

Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who...

UCB to acquire Candid Therapeutics, strengthening its immunology pipeline with novel T-cell engagers

UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and...

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

YARAL Pharma Inc. the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), announced that its Diclofenac Epolamine Topical System 1.3%, the authorized generic of Flector® (diclofenac epolamine) topical system 1.3%, is now...

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

SQ Innovation, developer of Lasix® ONYU, announced two important regulatory milestones in its international expansion strategy: the receipt of a CE marking certificate for the Lasix ONYU device, and the acceptance of Lasix ONYU by the European...

Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

Rapid Nexus Nanotech Wound Solutions, Inc., a California-based medical technology company, announced it has secured supply contracts with the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) and will begin commercial...

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard, will present advancements related to TfR1 CapX™. A leading...

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely...

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2...

Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

Ascletis Pharma Inc. announces completion of enrollment in its 13-week U.S. Phase II study (NCT07321678) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the...

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced new clinical data demonstrating a significant association between femoral subchondral bone shape, measured by B-score, and meniscal pathology in patients with knee...

Bristol Myers Squibb and Pfizer to provide Eliquis® (apixaban) through the Mark Cuban Cost Plus Drug Company

The Bristol Myers Squibb-Pfizer Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis® (apixaban) on CostPlusDrugs.com. Eliquis is one of the most widely prescribed oral...

CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal...